Measuring What Matters: Steroid-toxicity and Patient Outcomes
Ten years ago, two clinical researchers walked into a bar and, over a beer, asked themselves whether the direct measurement of steroid-toxicity would ever be possible. Today, Steritas, in licensing ...
The Digital Tool Helping Neurologists Be Patient-Loving Physicians
Myasthenia gravis is a rare immune-mediated disorder (affecting less than 100,000 patients in the US) in which the immune system mistakenly targets nerves or muscles. Historically, myasthenia gravis ...
In Conversation With… Glenn Philips, PhD
“We're using the same tools that demonstrate the benefit of our drugs to show that the long-term cost of steroids has been vastly underestimated.” Glenn Philips, PhD is the Vice President of Health ...
Quantifying the Risk-Benefit Ratio of Steroids in Myasthenia Gravis
A pioneering analysis of electronic health record (EHR) data from the Optum® EHR database has shown that it is finally possible to quantify the risk-to-benefit ratio of prescribing glucocorticoids, ...
Reshaping the Steroid Paradox
During 2023, the Steritas team had the opportunity to speak with a range of inspiring clinical research leaders who shared their expertise with us and our colleagues. Every conversation underscored ...
Curious about the true cost of steroid-toxicity?
Download our infographic today
